Since PSMA expression is confined to the tumor neovasculature, and several case reports demonstrated high PSMA uptake in vascular tumors [20, 21], we extended our cohort to include benign, intermediate, and malignant vascular tumors of bone and soft tissue (Fig. 5). Here, FOLH1 is linked to cancer.